More than 1,800 employees at the Bern facility develop and manufacture innovative biotherapies derived from human plasma.
R&D Switzerland at a glance: We are strengthening our local R&D network to contribute to our global strategic goals.
We are proud to work in the field of rare and serious diseases and to provide therapy in many areas of treatment.
We also aim to make sure that nothing holds you back from getting the therapies you need.
Every day at CSL Behring, we work as if someone's life depends on it, because it does.
CSL Behring biotherapies are manufactured in state-of-the-art facilities under stringent, controlled conditions.
Help us deliver our promise to save lives and protect the health of people.
Grow with us: CSL Behring offers university graduates an interesting career as a trainee.
Popular search terms:
News from our Protinus Project
Shaping the future of healthcare
Biomedical Science Award and Bernese Environmental Research Award
CSL Behring hosts Federal Councillor and Moroccan Trade Minister.
On 29 February, the Burgerspital Bern lit up in the colours of Rare Disease Day.
The contribution of R&D
CSL reported net income after tax of $2.02 billion in the first half of 2024.
On 29 February 2024, the Rare Disease Day will take place.
As part of a visit to the cantonal government, a visit to CSL Behring in Bern was also on the agenda.
Swissmedic Authorises CSL’s HEMGENIX® as First Gene Therapy for Hemophilia B
Americas
Asia Pacific
Middle East
Europe
